MarketPeel
Insider Trading Intelligence
Pricing
…
CS

Christobel Selecky

IBRX
DIRECTOR · IMMUNITYBIO, INC. · CIK 0001849739
FILING MIX · LIFETIME52%/48%
BUYS
17
SELLS
16
TOTAL VALUE
$4.06M
COMPANIES
1
ACTIVE SINCE
May 2021
HOLDINGS NOW
0
AVG SELL PX
$8.42
TRADE KIND
SHOWING 33 / 33
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 8 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Christobel Selecky, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+33.33%+4.96%+0.96%+4.00%+5.62%—
14d3+66.67%-1.04%+0.40%-1.45%-4.08%—
30d3+33.33%+7.55%-1.39%+8.94%+9.13%—
60d3+33.33%+18.38%-0.89%+19.27%+34.99%—
90d3+33.33%+10.44%+3.02%+25.92%+25.92%—
180d3(2 pending)+0.00%+42.75%+8.70%+34.05%+34.05%—
1y3(3 pending)——————
2y3(3 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
IBRX · 0 shares · as of Jul 1, 2026
041,98483,969125,953167,93720222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 17 buys / 16 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
159,478$9.02$1.44M0Jul 1, 2026Jul 6, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
35,064——0Jul 1, 2026Jul 6, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
124,414$2.99$372.0K159,478Jul 1, 2026Jul 6, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
124,414——0Jul 1, 2026Jul 6, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
35,064$2.98$104.5K35,064Jul 1, 2026Jul 6, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
700——35,064Jun 30, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
700$2.98$2.1K700Jun 30, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
300——124,414Jun 30, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
1,000$9.00$9.0K0Jun 30, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
300$2.99$8971,000Jun 30, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
32,173——35,764Jun 29, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
30,000$2.84$85.2K95,722Jun 29, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
95,722$9.01$862.2K0Jun 29, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
33,549——124,714Jun 29, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
33,549$2.99$100.3K65,722Jun 29, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
30,000——132,786Jun 29, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
32,173$2.98$95.9K32,173Jun 29, 2026Jul 1, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASEGRANT
Stock grant
65,600——65,600Jun 9, 2026Jun 10, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
25,000$2.98$74.5K25,000Feb 23, 2026Feb 24, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
25,000$10.00$250.0K0Feb 23, 2026Feb 24, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
25,000——67,937Feb 23, 2026Feb 24, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
25,000$2.98$74.5K25,000Jan 20, 2026Jan 21, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
25,000——92,937Jan 20, 2026Jan 21, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
25,000$7.51$187.7K0Jan 20, 2026Jan 21, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASE
50,000$2.98$149.0K50,000Jan 16, 2026Jan 21, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE
50,000——117,937Jan 16, 2026Jan 21, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
SALE10b5-1
10b5-1 plan
50,000$5.00$250.0K0Jan 16, 2026Jan 21, 2026 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASEGRANT
Stock grant
162,786——162,786Jun 18, 2025Jun 20, 2025 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASEGRANT
Stock grant
77,633——77,633Jun 11, 2024Jun 13, 2024 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASEGRANT
Stock grant
158,263——158,263Jun 13, 2023Jun 15, 2023 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASEGRANT
Stock grant
167,937——167,937Jun 14, 2022Jun 15, 2022 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASEGRANT
Stock grant
26,064——26,064Jun 10, 2021Jun 14, 2021 ↗View →
IBRX
IMMUNITYBIO, INC.
PURCHASEGRANT
Stock grant
21,873——21,873May 3, 2021May 5, 2021 ↗View →
Other insiders · IBRX
Loading peer insiders…
About this filer
CIK 0001849739
ROLE
Director
PRIMARY
IBRX
COMPANIES
1
ACTIVE SINCE
May 2021
MARKETPEEL · /INSIDER/0001849739DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback